文献速递临床试验与 GCP

概念验证研究动态扩展至剂量探索的两阶段设计

Dynamic development paths for expanding a proof-of-concept study to explore dose range.
PubMed 文献 · Stat Med · 2018-06-21

针对II期临床中概念验证与剂量探索两个关键目标,本文提出一种两阶段设计:第一阶段用高剂量与安慰剂比较产生早期疗效信号,若成功则第二阶段采用「Go Fast」计划扩展当前研究并加入低剂量探索疗效剂量范围;否则采用「Go Slow」策略以缩减样本量仅保留高剂量和安慰剂。

要点

  • 第一阶段高剂量对照安慰剂产生早期疗效信号。
  • 信号成功则第二阶段扩展研究并加入低剂量探索剂量范围。
  • 信号失败则缩减样本量仅保留高剂量和安慰剂。

核心结论

  • 提出两阶段设计将概念验证与剂量探索整合于同一研究框架。
  • 根据第一阶段疗效信号决定采用「Go Fast」扩展或「Go Slow」缩减策略。

研究设计与样本

  • 两阶段设计,第一阶段为高剂量与安慰剂对照产生早期疗效信号,第二阶段根据结果选择扩展或缩减。

临床怎么用

  • 在II期临床中可依据第一阶段信号动态调整后续研究路径与样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In Phase II clinical development of a new drug, the two most important deliverables are proof of concept (PoC) and dose ranging. Traditionally, a PoC study is designed as the first Phase II clinical trial. In this PoC, there are two treatment groups-a high dose of the study medication, against the placebo control. After the concept is proven, the next Phase II study is a dose-ranging design with many test doses. This paper proposes a two-stage design with the first stage attempting to generate an early signal of efficacy. If successful, the second stage will adopt a "Go Fast" plan to expand the current study and add lower study doses of the test drug to explore the efficacy dose range. Otherwise, a "Go Slow" strategy is triggered, and the study will stop at a reduced sample size with high dose and placebo only.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Deng Q, Bai X, Ting N, et al. Dynamic development paths for expanding a proof-of-concept study to explore dose range. Stat Med. 2018. PMID: 29926481. doi:10.1002/sim.7840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。